文献速递血管炎

巨细胞动脉炎超声评分(OGUS)在诊断时及初始治疗后预测患者未来复发:一项多中心前瞻性研究结果

The giant cell arteritis (GCA) ultrasound score (OGUS) at diagnosis and after initial treatment predicts future relapses in GCA patients: results of a multicentre prospective study.
PubMed 文献 · Ann Rheum Dis · 2025-02-06

这项多中心前瞻性研究纳入97例新发巨细胞动脉炎(GCA)患者,在固定时间点进行系列超声评估,采用OMERACT GCA超声评分(OGUS)量化血管壁异常。诊断时OGUS较高与12个月内复发风险增加相关(每增加1分IRR 1.85,95%CI 1.05-3.32),而前3周内OGUS正常化(评分<1)与后续复发减少相关(IRR 0.44,95%CI 0.22-0.88)。

要点

  • 诊断时OGUS每增加1分,12个月内复发风险增加(IRR 1.85,95%CI 1.05-3.32)。
  • 前3周内OGUS正常化(评分<1)与后续复发减少相关(IRR 0.44,95%CI 0.22-0.88)。
  • 前12周OGUS下降与启动改善病情抗风湿药(DMARDs)呈负相关。

核心结论

  • 超声在GCA中具有预后价值,可辅助风险分层。
  • 诊断时OGUS较高与复发相关,而前几周内改善程度更高、速度更快与较低复发率相关。

研究设计与样本

  • 前瞻性、多中心研究,纳入新发GCA患者,在固定时间点进行系列超声评估。
  • 共97例患者,849次访视。
  • 采用OMERACT GCA超声评分(OGUS)量化血管壁异常。
  • 复发定义为GCA相关症状复发或炎症标志物升高需要治疗。
  • 采用含稳健方差估计的多变量泊松模型,纳入年龄、性别、大血管型GCA、糖皮质激素累积剂量和基线OGUS作为协变量。

主要发现

  • 35例(36.1%)患者共经历66次复发,中位复发时间210天(IQR 94.5-323.5)。
  • 诊断时OGUS较高与12个月内复发风险增加相关(OGUS每增加1分IRR 1.85,95%CI 1.05-3.32)。
  • 多变量分析中,前3周内OGUS正常化(评分<1)与后续复发呈负相关(IRR 0.44,95%CI 0.22-0.88),并预测首次复发时间。
  • 前12周OGUS下降与启动DMARDs呈负相关。
  • 缺血性/主动脉并发症罕见。

关键数值与推荐

  • 复发定义:GCA相关症状复发或炎症标志物升高需要治疗。
  • OGUS正常化定义为评分<1。
  • 诊断时OGUS每增加1分,12个月内复发IRR 1.85(95%CI 1.05-3.32)。
  • 前3周OGUS正常化与后续复发IRR 0.44(95%CI 0.22-0.88)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To test the prognostic role of ultrasonography at diagnosis of giant cell arteritis (GCA) and the change of ultrasound abnormalities during the initial weeks of follow-up for the prediction of relapse, vascular complications, or initiation of disease-modifying antirheumatic drugs (DMARDs). METHODS: Prospective, multicentre study of patients with new onset GCA undergoing serial ultrasound assessment at fixed time points. The Outcome Measures in Rheumatology (OMERACT) GCA ultrasonography score (OGUS) was used to quantify vessel wall abnormalities. Relapse was defined as recurrence of GCA-related symptoms or rise of inflammatory markers requiring treatment. A multivariable Poisson model with robust variance estimator was applied, including age, sex, large vessel GCA, glucocorticoid cumulative dose, and baseline OGUS as covariates. RESULTS: Ninety-seven patients were assessed in 849 visits. Thirty-five (36.1%) patients experienced a total of 66 relapses, with median time to relapse of 210 days (IQR, 94.5-323.5). Higher OGUS at diagnosis was associated with an increased risk of relapse within 12 months (incidence rate ratio [IRR] for each 1 point increase in OGUS: 1.85; 95% CI, 1.05-3.32). At multivariable analysis, OGUS normalisation (score <1) over the first 3 weeks was negatively associated with subsequent relapses (IRR, 0.44; 95% CI, 0.22-0.88) and predicted time to first relapse. OGUS reduction over the first 12 weeks was inversely associated with initiation of DMARDs. Ischaemic/aortic complications were rare. CONCLUSIONS: Ultrasonography has a prognostic role in GCA and can inform risk stratification. Higher OGUS at diagnosis is associated with relapse, while a higher degree and rapidity of improvement in the first weeks are linked with lower relapse rate.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Monti S, Ponte C, Schäfer VS, et al. The giant cell arteritis (GCA) ultrasound score (OGUS) at diagnosis and after initial treatment predicts future relapses in GCA patients: results of a multicentre prospective study. Ann Rheum Dis. 2025. PMID: 39919971. doi:10.1016/j.ard.2025.01.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。